Hadong Kim

Hadong Kim

Auto-generated profile, based on publicly available information

Hadong Kim

Pin Therapeutics, Seongnam-si, Republic of Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JKJinhyuk Kim
Jinhyuk Kim
HJHaiyan Jin
Haiyan Jin
HKHadong Kim
Hadong Kim
SMSungho Moon
Sungho Moon
JKJin Kwan Kim
Jin Kwan Kim
GHGyoonhee Han
Gyoonhee Han
Polo-like kinase 1 (PLK1) is a key regulator of mitotic progression and represents an attractive target for anticancer therapy. However, the development of PLK1 inhibitors has been limited by challenges in achieving kinase selectivity and optimal pharmacokinetic properties. Here, we report the development of BA-0443, a novel PLK1 inhibitor identified through a computationally guided design strategy. Structure-based modeling and molecular simulations were employed to derive approaches for improving kinase selectivity, while fragment molecular orbital (FMO) analysis supported favorable binding interactions with PLK1. Guided by these insights, BA-0443 was designed and synthesized to retain potent PLK1 inhibition (IC50 = 3.7 nM) while reducing off-target kinase activity. In addition, BA-0443 exhibits improved pharmacokinetic properties, including enhanced systemic exposure and prolonged circulation time (T1/2 = 5.98 h, AUC = 4330 ng·h/mL), supporting sustained target engagement in vivo. Collectively, BA-0443 represents a promising PLK1 inhibitor that integrates rational design with improved selectivity and pharmacokinetic performance.

3 November 2026
Verified
Other
Open access
BKBo-Reum Kim
Bo-Reum Kim
HKHyemin Kim
Hyemin Kim
HCHoon Choi
Hoon Choi
DKDaehun Kwag
Daehun Kwag
YKYoon-Ju Kim
Yoon-Ju Kim
BCByung-Sik Cho
Byung-Sik Cho
Cell-cycle analysis in AML cell lines following PinA1 treatment.

3 November 2026
Verified
Other
Open access
BKBo-Reum Kim
Bo-Reum Kim
HKHyemin Kim
Hyemin Kim
HCHoon Choi
Hoon Choi
DKDaehun Kwag
Daehun Kwag
YKYoon-Ju Kim
Yoon-Ju Kim
BCByung-Sik Cho
Byung-Sik Cho
CK1α degradation and p21 induction in tumor tissues following PinA1 treatment in MV4-11 xenograft models.

3 August 2026 in Cancer Research
Verified
Journal Article
Open access
BKBo-Reum Kim
Bo-Reum Kim
HKHyemin Kim
Hyemin Kim
HCHoon Choi
Hoon Choi
DKDaehun Kwag
Daehun Kwag
YKYoon-Ju Kim
Yoon-Ju Kim
BCByung-Sik Cho
Byung-Sik Cho
Casein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degrading target proteins. In this study, we developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in preclinical AML models. PinA1 preferentially degraded CK1α at nanomolar concentrations, resulting in enhanced p53 expression, cell-cycle arrest, and apoptosis in TP53 wild-type AML cell lines but not in TP53-mutated cells. PinA1 also induced CK1α degradation and p53-dependent apoptosis in primary AML cells with wild-type TP53. Notably, PinA1 had minimal effects on the viability of human peripheral blood and bone marrow mononuclear cells, including CD34+ cells, with limited activation of the p53 pathway. In both cell lines and primary AML cells, PinA1 enhanced apoptosis when combined with targeted agents, including FLT3, BCL-2, or MDM2 inhibitors. PinA1 demonstrated robust antileukemic efficacy as a monotherapy and exhibited synergistic effects when combined with targeted agents in xenografts derived from human AML cell lines and primary AML cells. In conclusion, PinA1 degrades CK1α, activates the p53 pathway, and induces cell-cycle arrest and apoptosis in TP53 wild-type AML cells. The robust antileukemic efficacy of PinA1, both as monotherapy and further in combination with targeted agents, along with its minimal toxicity to normal hematopoietic cells, underscores its potential for future clinical applications. Significance: PinA1 is a selective molecular glue degrader of CK1α that activates p53 signaling, induces apoptosis in TP53 wild-type acute myeloid leukemia, spares normal hematopoietic cells, and shows strong synergy with targeted therapies.

3 November 2026
Verified
Other
Open access
BKBo-Reum Kim
Bo-Reum Kim
HKHyemin Kim
Hyemin Kim
HCHoon Choi
Hoon Choi
DKDaehun Kwag
Daehun Kwag
YKYoon-Ju Kim
Yoon-Ju Kim
BCByung-Sik Cho
Byung-Sik Cho
Figure S1 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells

3 November 2026
Verified
Other
Open access
BKBo-Reum Kim
Bo-Reum Kim
HKHyemin Kim
Hyemin Kim
HCHoon Choi
Hoon Choi
DKDaehun Kwag
Daehun Kwag
YKYoon-Ju Kim
Yoon-Ju Kim
BCByung-Sik Cho
Byung-Sik Cho
Supplementary Tables for manuscript.